Alprazolam: Nursing Drug Guide, Respiratory Depression & Hold Rules
Short-acting benzodiazepine for anxiety and panic disorder—on shift, the highest-stakes risk is stacking alprazolam with opioids, alcohol, or other CNS depressants and missing early respiratory depression, oversedation, or a non-tapered stop after continued use.
Alprazolam carries a boxed warning: concomitant benzodiazepines with opioids may cause profound sedation, respiratory depression, coma, and death. The same additive CNS depression occurs with alcohol and other sedating drugs. Before every dose, reconcile the MAR and home meds for overlapping sedatives, assess respiratory rate and sedation, and hold if the patient is excessively sedated or hypoxic. Abrupt discontinuation after continued use can precipitate life-threatening withdrawal (including seizures)—never stop or skip a taper without prescriber/pharmacy orders.
📋 Contents
⚡ Quick facts
💡 Key takeaway
Before alprazolam: check for opioids, alcohol, and other CNS depressants on the MAR and home list; assess RR, SpO2, and sedation. Hold when oversedated, hypoxic, or a strong CYP3A inhibitor is starting (except ritonavir per label). After continued use, taper slowly—do not abruptly stop. Escalate immediately for respiratory depression; overdose management may include flumazenil with seizure-risk precautions.
Most common brand names
Alprazolam is a Schedule IV benzodiazepine supplied as immediate-release tablets and extended-release formulations. Verify strength (0.25 mg, 0.5 mg, 1 mg, 2 mg) and whether the order is for short-acting tablets or XR on every administration pass.
Common U.S. brand examples include Xanax (immediate-release tablets) and Xanax XR (extended-release). Generic alprazolam tablets are widely dispensed. Do not substitute XR for immediate-release—or vice versa—without a prescriber order and pharmacy verification.
Why we give it — Indications
Alprazolam is indicated for adults with generalized anxiety disorder (acute treatment) and panic disorder with or without agoraphobia. It is a short-acting anxiolytic—not first-line for every patient with worry or stress; use the lowest effective dose for the shortest duration and reassess the need for continued therapy per prescribing information.
| Use | Detail |
|---|---|
| Generalized anxiety disorder (GAD) | Acute treatment in adults. Starting oral dosage 0.25 mg to 0.5 mg three times daily; may increase every 3 to 4 days to a maximum recommended daily dose of 4 mg in divided doses. Use the lowest possible effective dose. |
| Panic disorder (PD) | Treatment in adults with or without agoraphobia. Starting oral dosage 0.5 mg three times daily; may increase every 3 to 4 days in increments of no more than 1 mg per day. Controlled trials included daily dosages in the range of 1 mg to 10 mg (mean approximately 5 mg to 6 mg daily). |
| Not an opioid analgesic | Do not use for pain control. If the patient also receives opioids for pain, the boxed warning for combined benzodiazepine–opioid use applies—see safety and hold sections. |
On a small screen, swipe or scroll sideways to see the full table.
How it works
Alprazolam is a 1,4 benzodiazepine (triazolobenzodiazepine) that binds the benzodiazepine site of GABAA receptors in the brain and enhances GABA-mediated synaptic inhibition. Clinical effects include anxiolysis, sedation, muscle relaxation, and anticonvulsant activity at higher levels. Because it depresses central respiratory drive—especially when combined with other CNS depressants—nurses must treat sedation and respiratory rate as primary safety endpoints, not secondary comfort measures.
Dosing overview
Dosing depends on indication, age, hepatic function, and interacting drugs. Verify each order against current prescribing information and the patient’s opioid and CNS depressant exposure before administration.
Missed dose: If a scheduled dose is late, give per prescriber and facility policy only if the next dose will not stack sedation with recent opioids or other CNS depressants. Do not double doses. If the patient is already oversedated, hold and clarify.
Before you give it — Safety check
Pretreatment checks
- Screen the MAR and home med list for opioids, alcohol, sedating antihistamines, and other benzodiazepines—perform medication reconciliation on admission and after every transfer
- Assess respiratory rate, oxygenation (pulse oximetry per protocol), sedation level, and mental status; review history of COPD, severe pulmonary disease, or sleep apnea
- Confirm allergy to alprazolam or other benzodiazepines; verify tablet strength and whether a taper is in place if therapy is being reduced
Contraindications
- Known hypersensitivity to alprazolam or other benzodiazepines (angioedema reported)
- Concomitant use with strong CYP3A inhibitors (e.g., ketoconazole, itraconazole)—except ritonavir, which requires dose adjustment per labeling
Important interactions
| Drug / class | Effect | Nursing action |
|---|---|---|
| Opioid analgesics (e.g., morphine) | Boxed warning: profound sedation, respiratory depression, coma, and death. Observational data show increased drug-related mortality versus opioids alone. | Reserve combined use only when alternatives are inadequate; use lowest doses and shortest duration; hold alprazolam if new opioid starts or sedation increases—notify prescriber/pharmacist same shift |
| Other CNS depressants (alcohol, other benzodiazepines, sedating drugs) | Additive sedation and respiratory depression | Assess for alcohol use; clarify if duplicate benzodiazepine therapy (lorazepam, diazepam) is intentional |
| Strong CYP3A inhibitors | Marked increase in alprazolam concentrations (contraindicated except ritonavir with mandated dose reduction) | Hold alprazolam when a strong inhibitor is newly prescribed unless prescriber/pharmacy documents a safe plan |
| Comorbid depression | Benzodiazepines may worsen depression; panic disorder is associated with major depressive disorders and suicide risk in untreated patients | Limit prescription quantity when feasible; monitor for worsening mood or suicidal ideation; escalate per mental health protocol |
On a small screen, swipe or scroll sideways to see the full table.
Concomitant benzodiazepines with opioids may cause profound sedation, respiratory depression, coma, and death. The same additive risk applies to alcohol and other CNS depressants. Before every dose, confirm whether combined therapy is still necessary, assess RR and sedation, and hold when the patient is oversedated or hypoxic.
Administration
Route: Oral (immediate-release tablets; extended-release products per separate labeling). Tablets are available as 0.25 mg, 0.5 mg, 1 mg, and 2 mg strengths.
- Give with or without food per product labeling; swallow tablets whole unless pharmacy approves splitting of scored products
- Controlled substance (Schedule IV): follow institutional controlled-drug counting, wasting, and secure storage requirements
- Do not crush or split extended-release (XR) formulations unless explicitly ordered and verified by pharmacy
- When ritonavir is co-prescribed, labeling requires dose reduction to half the recommended alprazolam dose when therapy starts together, then titration to target after 10–14 days—coordinate with pharmacy
Labeling cautions against driving or operating machinery until effects of concomitant CNS depressants (including opioids) are known. Implement fall precautions, bed alarm as appropriate, and supervise ambulation after doses in older adults or sedated patients.
Expected therapeutic response
- Reduced anxiety symptoms and panic attack frequency when used for labeled indications—assess with patient report and clinical observation, not sedation alone
- Calmer affect without excessive somnolence, slurred speech, or inability to arouse for conversation
- Stable respiratory rate and oxygenation; perform neurological assessment when sedation increases or mental status changes
- If anxiety returns between doses (interdose symptoms in panic disorder), notify prescriber—may indicate tolerance or dosing interval issues rather than automatic dose escalation by nursing
Red flags — Stop and act
Respiratory depression with benzodiazepines—especially plus opioids or alcohol—can progress to coma and death. Deaths have been reported in patients with severe pulmonary disease shortly after initiation. Escalate immediately.
- Respiratory rate below facility threshold, shallow breathing, apnea, or new difficulty breathing—hold alprazolam, stimulate/support airway per protocol, rapid response
- SpO2 drop, cyanosis, or inability to arouse the patient—treat as respiratory emergency; consider opioid co-ingestion
- Excessive sedation, slurred speech, ataxia, or altered mental status after a dose or dose increase
- New confusion, paradoxical agitation, or violent behavior (rare disinhibitory reaction)
- Angioedema, facial swelling, urticaria, or anaphylaxis after a dose—stop permanently unless allergy service approves rechallenge
- Seizure activity or known withdrawal signs after missed doses, abrupt stop, or flumazenil—urgent prescriber and neurology input; patients with epilepsy are at elevated risk with abrupt changes
Adverse effects
| Adverse effect | Frequency / severity | Nursing response |
|---|---|---|
| Drowsiness, light-headedness, fatigue | Very common in GAD and panic trials (e.g., drowsiness 41% GAD, 77% panic vs lower placebo rates) | Assess sedation before ambulation; hold next dose if oversedated; screen for opioid/alcohol co-use |
| Impaired coordination, dysarthria, dizziness | Common; impaired coordination 40% in panic trials | Fall precautions; notify prescriber if functionally limiting |
| Memory impairment, irritability, cognitive effects | Reported in panic disorder trials | Document baseline and changes; avoid further dose increases without prescriber review |
| Hypotension | Reported (5% GAD trials) | Monitor BP; orthostatic checks when sedated |
| Insomnia (discontinuation-emergent) | 29.5% upon discontinuation in panic disorder database | Distinguish withdrawal from return of illness; do not restart full dose without orders—taper per protocol |
| Respiratory depression | Serious; increased with opioids, alcohol, pulmonary disease | Hold drug; airway support; escalate; contact local poison control or medical toxicology per facility protocol if overdose suspected |
On a small screen, swipe or scroll sideways to see the full table.
Overdose, toxicity, and antidote
Benzodiazepine overdosage ranges from drowsiness to coma. Severe cases may include respiratory depression. Combined overdose with opioids, alcohol, or other CNS depressants may be fatal. Markedly abnormal vital signs suggest polysubstance involvement.
Early signs
- Somnolence, confusion, dysarthria, ataxia, hypotonia, diminished reflexes
- Paradoxical agitation, irritability, or talkativeness (less common)
- Progressive respiratory depression and coma—especially with co-ingested opioids
Antidote and supportive care
Flumazenil is the specific benzodiazepine receptor antagonist indicated for complete or partial reversal of benzodiazepine sedation in overdosage management. It is an adjunct to airway management—not a substitute. Flumazenil may precipitate withdrawal and seizures, especially with chronic benzodiazepine use, mixed overdoses, or underlying seizure disorders; it is contraindicated when benzodiazepines were given for a potentially life-threatening condition (e.g., status epilepticus).
If opioids are co-involved, naloxone may reverse opioid-mediated respiratory depression per protocol—benzodiazepine effects may persist. Employ supportive measures including IV fluids and airway management per escalation pathways.
Contact local poison control or medical toxicology services for overdose guidance per facility protocol and local emergency guidance. Do not delay airway support while obtaining consultation.
Look-alike / sound-alike and error prevention
- Alprazolam vs lorazepam vs diazepam—all are benzodiazepines but differ in potency, duration, and taper plans; verify MAR name and strength
- Xanax vs Xanax XR—different release profiles; do not interchange
- Strength mix-ups—0.25 mg, 0.5 mg, 1 mg, and 2 mg tablets; the 2 mg bar is a high-dose unit—independent double-check
- Alprazolam vs triazolam—both are triazolobenzodiazepines; sound-alike risk in verbal orders
- Duplicate benzodiazepine therapy—home Xanax plus ordered lorazepam PRN is a common sedation stack
- Opioid + benzodiazepine orders—two high-risk sedatives on one MAR; requires documented necessity and respiratory monitoring plan
Practical bedside notes
| Topic | Bedside guidance |
|---|---|
| Onset | Peak plasma concentration approximately 1–2 hours after oral dose; sedation may be apparent sooner—do not repeat early doses without orders. |
| Half-life | Mean approximately 11 hours in healthy adults (longer in older adults, obesity, hepatic impairment)—effects may linger into the next shift. |
| Controlled substance | Schedule IV—secure storage, witness waste, and diversion precautions per policy. |
| PRN anxiety orders | Clarify maximum daily dose and minimum interval; document indication and response each time. |
| Commonly missed | Home benzodiazepines not on admission list; new night opioid without reassessing daytime alprazolam. |
| Ask pharmacy when | CYP3A inhibitor starts or stops, ritonavir co-therapy, hepatic dose questions, or taper order ambiguity. |
On a small screen, swipe or scroll sideways to see the full table.
High-risk populations
| Population | Considerations |
|---|---|
| Opioid co-therapy | Boxed warning population—lowest effective doses, shortest duration, and close monitoring for respiratory depression and sedation. Hold when opioids are escalated or patient is somnolent. |
| Severe pulmonary disease / impaired respiratory function | Deaths reported shortly after initiation in severe pulmonary disease. Discontinue if hypoventilation, respiratory depression, or apnea occurs. |
| Older adults | Start 0.25 mg two or three times daily; increased sensitivity to sedation and falls. Reduce dose if adverse reactions occur at starting dose. |
| Hepatic impairment | Start 0.25 mg two or three times daily; slow titration; reduce dose if intolerance occurs. |
| Substance use / misuse risk | Assess abuse, misuse, and addiction risk before and during therapy; avoid stacking with alcohol or illicit CNS depressants. |
| Pregnancy / lactation | Late pregnancy use may cause neonatal sedation and withdrawal. Labeling states breastfeeding is not recommended because of potential serious adverse reactions in infants. |
On a small screen, swipe or scroll sideways to see the full table.
Monitoring and documentation
Monitor
- Respiratory rate, depth, and SpO2—especially when opioids or alcohol are present or pulmonary disease is documented
- Sedation level (e.g., Pasero scale or facility tool), ability to arouse, and blood pressure for hypotension
- Mental status and anxiety/panic symptom response—sedation is not a proxy for therapeutic benefit
- Withdrawal signs if doses are delayed, reduced, or held: tremor, tachycardia, rebound anxiety, insomnia, seizures
Document
- Dose, route, time, indication, and patient response including respiratory status before and after
- Co-administered opioids or CNS depressants on the same shift; any hold and prescriber/pharmacist notification
- Controlled-drug count alignment; taper plan and patient education on why abrupt stops are dangerous
Patient teaching
- Do not combine with alcohol, opioid pain medicines, or other sedating drugs unless your prescriber explicitly directs you—and report increased sleepiness immediately
- Do not drive or operate machinery until you know how alprazolam affects you, especially when starting or increasing dose or when taking opioids
- Never stop suddenly after regular use—withdrawal can be life-threatening (seizures); ask for a taper plan
- Keep medication secure (controlled substance); do not share tablets
- Seek urgent care for severe sleepiness, slow or troubled breathing, or inability to stay awake—and contact local poison control or toxicology services per your facility’s overdose guidance
The Hold Rule
Do not give and contact the prescriber/pharmacist when:
- Known alprazolam or benzodiazepine allergy, angioedema, or anaphylaxis after prior dose
- Excessive sedation, respiratory depression, hypoventilation, apnea, or SpO2 below protocol threshold
- New or escalated opioid, other benzodiazepine, or sedating drug without documented prescriber approval for continued alprazolam
- Strong CYP3A inhibitor started (except ritonavir with pharmacy-managed dose adjustment plan)
- Suspected overdose or patient cannot be safely aroused
- Order to stop abruptly after continued use without a taper—clarify taper before withholding long-term therapy without a plan
- Severe pulmonary deterioration after initiation—labeling instructs discontinuation if respiratory depression occurs
Hold parameters may vary by institutional protocol. Follow prescriber orders, pharmacy guidance, and facility policy.
Clinical practice integration and workflow
Alprazolam is familiar on medical–surgical units, but the boxed warning for opioid co-use makes it a respiratory safety drug—not a low-risk PRN. Build opioid and sedation checks into every pass, especially after new postoperative analgesia orders.
1. Check-before-you-give protocol
- Right patient, drug, dose, route, time—and right respiratory and sedation assessment
- Scan MAR and home list for opioids, alcohol history, and duplicate benzodiazepines
- Compare respiratory rate and SpO2 to pre-dose baseline; hold if trending worse
- Confirm taper or stable maintenance plan if therapy is being reduced—never skip taper doses without orders
2. High-alert and safety badge
High respiratory risk with opioids and CNS depressants (boxed warning)Many institutions treat opioid–benzodiazepine combinations with enhanced monitoring or hard stops. Follow facility opioid–benzo policies even when the patient has taken the combination at home.
3. Clinical workflow: hold and question rules
- If a postoperative patient receives new IV opioid boluses or PCA escalation, reassess whether scheduled or PRN alprazolam is still appropriate the same shift
- If the patient sleeps through assessments or cannot participate in care, hold and notify prescriber—may need dose reduction or alternate anxiolytic strategy
- For suspected overdose, activate airway support and contact local poison control or toxicology per protocol before focusing on reversal agents alone
4. Critical teach-back questions
- “What medicines or alcohol should you avoid while taking alprazolam?” (Patient should name opioids, other sedatives, and alcohol unless prescriber approved.)
- “What will you do if you become very sleepy or your breathing feels slow?” (Patient should seek urgent help and not take the next dose.)
5. Care coordination
Pharmacist: Review opioid–benzodiazepine necessity, CYP3A interactions, taper schedules, and flumazenil risk if overdose reversal is considered
Prescriber / mental health: Notify for uncontrolled anxiety on current dose, suicidal ideation in comorbid depression, dependence concerns, or need for slower taper
🧠 Quick mental checklist
- Is the patient on opioids, other benzodiazepines, or alcohol today—and is RR/SpO2 safe?
- Am I about to oversedate someone with pulmonary disease or sleep apnea risk?
- Is this a new dose, new interaction, or missed taper dose that could trigger withdrawal?
- If I hold alprazolam, do I need a taper plan rather than an abrupt stop?
- If overdose is suspected, is airway support underway and local poison control contacted per protocol?
Alprazolam NCLEX practice questions
This NCLEX-style clinical judgment practice set for alprazolam uses a tabbed inpatient case (MAR, vitals, history, nursing notes), then rotates priority action, cue recognition, trend interpretation with respiratory status, matrix urgency sorting, clinical judgment, and cloze reversal selection—recognise cues → analyse → prioritise → act → evaluate outcomes.
Select a tab to view MAR, vitals, history, and nursing note details for this case.
- Alprazolam 0.5 mg PO TID scheduled — 0800 and 1400 given
- Morphine 2 mg IV q4h PRN severe pain — 1 dose at 1300
- Alprazolam 0.25 mg PO q6h PRN anxiety — not given
- 2000: due alprazolam 0.5 mg; nurse reviewing case tabs before administration
- 0800: RR 16, SpO2 97% on room air, BP 118/72, HR 88, sedation score 0/10
- 1400 (post morphine + alprazolam): RR 11, SpO2 91% on room air, BP 102/58, HR 72, sedation score 4/10
- 1930: RR 9, SpO2 88%, patient difficult to arouse for conversation
- 62-year-old, postoperative day 1 laparoscopic colectomy
- History of panic disorder; home alprazolam 0.5 mg TID continued inpatient
- Obstructive sleep apnea on home CPAP (not at bedside this shift)
- Social history: occasional alcohol; none reported last 24 h
- 1300: Patient resting comfortably after morphine; denies chest pain
- 1800: Family reports patient “very sleepy” and snoring loudly
- 1930: Nurse unable to obtain reliable pain score; respirations shallow on observation
Answer key & rationale
Frequently asked questions
Why must nurses hold alprazolam when opioids or alcohol are involved?
Prescribing information carries a boxed warning that concomitant benzodiazepines with opioids can cause profound sedation, respiratory depression, coma, and death. Reserve combined use only when alternatives are inadequate, use the lowest doses for the shortest duration, and follow patients closely for respiratory depression and sedation. Hold and clarify if a new opioid dose, PRN sedative, or alcohol use would stack CNS depression without prescriber approval.
When should a nurse hold alprazolam and call the prescriber or pharmacist?
Hold for known hypersensitivity, strong CYP3A inhibitors (except ritonavir per labeling), excessive sedation or respiratory depression, suspected overdose, or orders to stop abruptly without a taper after continued use.
What reversal agent is used for benzodiazepine overdose?
Flumazenil is listed in prescribing information for complete or partial reversal of benzodiazepine sedation. It can precipitate withdrawal and seizures and is contraindicated when benzodiazepines control a life-threatening condition such as status epilepticus. Use with airway support and contact local poison control or medical toxicology per facility protocol.
Is alprazolam safe during breastfeeding?
Labeling states breastfeeding is not recommended during treatment because of sedation and withdrawal risk in infants. LactMed reports alprazolam in milk and infant sedation; shorter-acting alternatives may be preferred when therapy is needed during nursing.
How should alprazolam be discontinued?
Abrupt discontinuation after continued use may cause life-threatening withdrawal including seizures. Use a gradual taper—commonly no more than 0.5 mg every 3 days, slower if symptoms emerge. Pause or increase to the prior dose if withdrawal appears, then taper more slowly per prescriber/pharmacy guidance.
What should nurses monitor every shift?
Respiratory rate, oxygenation, sedation level, and mental status—especially with opioids, alcohol, sleep apnea, or pulmonary disease. Discontinue alprazolam if respiratory depression, hypoventilation, or apnea occurs per labeling.
References
-
U.S. National Library of Medicine. ALPRAZOLAM tablet — Full prescribing information. DailyMed.https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b3c55877-2538-4892-bdb1-d618c643d29c
-
U.S. National Library of Medicine. XANAX (alprazolam) tablet — Full prescribing information. DailyMed.https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=388e249d-b9b6-44c3-9f8f-880eced0239f
-
Drugs and Lactation Database (LactMed). Alprazolam. Bethesda (MD): National Institute of Child Health and Human Development.https://www.ncbi.nlm.nih.gov/books/NBK501199/
-
U.S. Food and Drug Administration. FDA requires strongest warning for prescription opioid pain and cough medicines used with benzodiazepines.https://www.fda.gov/drugs/drug-safety-and-availability/fda-requires-strongest-warning-prescription-opioid-pain-and-cough-medicines-used-with-or-addiction
Review and transparency
This medication guide is written and reviewed using NurseOnShift editorial and clinical review standards.
Educational use only. This content does not replace clinical judgment, prescriber orders, pharmacist guidance, product labeling, or institutional protocols.